U.S. Media Stock News

DaVita (DVA) is back in focus after quarterly earnings and revenue came in ahead of expectations, followed by analyst downgrades that put fresh attention on its future earnings guidance and capital allocation choices. See our latest analysis for DaVita. At a share price of $149.45, DaVita has given investors a 90 day share price return of 43.88%, while the 1 year total shareholder return of 2.17% looks modest alongside a much stronger 3 year total shareholder return of 79%. This suggests that...

If you are wondering whether T. Rowe Price Group at around US$95.84 is offering fair value or a potential mispricing, this article walks through the key numbers so you can judge for yourself. The stock has moved 7.4% over the last 7 days and 8.2% over the last 30 days, while the 1 year return stands at 15.3% and the year to date return is a decline of 8.4%, which gives you a mixed picture of recent momentum. These moves sit against a backdrop of ongoing interest in established asset managers...

On 14 April 2026, LocaliQ ANZ, the digital marketing solutions arm of USA TODAY Co., launched a next-generation AI Voice Agent within its Dash platform, adding 24/7 conversational call handling, transcription, real-time lead scoring and integrated scheduling for instant appointment booking. This rollout highlights how USA TODAY is embedding AI across the customer journey for business clients, aiming to improve lead conversion and operational responsiveness beyond traditional call-center and...

Neurocrine Biosciences released a new real world retrospective claims analysis on treatment persistence in tardive dyskinesia. The study compared INGREZZA (valbenazine) with AUSTEDO XR (deutetrabenazine) in adult patients over a six month period. Patients on INGREZZA showed higher continuation rates and lower treatment switching throughout the study window. Neurocrine Biosciences, listed as NasdaqGS:NBIX, puts this new data in front of investors at a time when the stock trades at $130.81...

Astera Labs (ALAB) is back in focus after investors pushed the stock higher for a seventh straight session, reacting to a high double digit first quarter growth outlook and rising interest in AI infrastructure exposure. See our latest analysis for Astera Labs. The recent run has flipped sentiment after a softer start to the year, with a 43.37% 7 day share price return lifting the latest share price to US$170.60. The 1 year total shareholder return of 183.95% also shows how strong interest in...

Over the last week, the United States market has seen a 4.4% increase, contributing to an impressive 32% rise over the past year, with earnings expected to grow by 16% annually. In such a thriving environment, identifying stocks that are potentially undervalued can offer investors opportunities for growth by focusing on companies with strong fundamentals and attractive valuations relative to their peers.

Matlantis has announced the integration of the NVIDIA ALCHEMI Toolkit into its platform, marking a significant advancement in industrial materials simulation. This collaboration has resulted in remarkable computational throughput and up to 10x speed improvements in critical calculations through the integration of NVIDIA's Warp-optimized kernels. Matlantis is further enhancing its simulation capabilities with the introduction of LightPFP, a lightweight simulation potential that scales...

If you are wondering whether Lam Research's current share price reflects its true worth, the recent performance gives plenty to think about. The stock last closed at US$272.41, with returns of 21.4% over 7 days, 28.4% over 30 days, 47.2% year to date, and 300.9% over 1 year. Recent commentary has focused on Lam Research as a key player in semiconductor equipment, with attention on how demand for chip manufacturing capacity may affect sentiment toward the stock. Broader discussion around...

Eli Lilly (NYSE:LLY) is acquiring CrossBridge Bio to add next generation dual payload antibody drug conjugates to its oncology pipeline. The deal brings in ADC candidates that target cancer driving proteins, broadening Lilly’s approach to precision cancer treatment. This move comes alongside Lilly’s existing programs in areas such as Jaypirca and GLP 1 therapies, and focuses on pipeline expansion through M&A. Eli Lilly, trading at around $922.5 per share, has seen a 22.7% gain over the past...

Event overview Parsons (PSN) has drawn investor attention after recent trading, with the stock last closing at US$56 and showing mixed returns over the past year, including a decline over the past 3 months. See our latest analysis for Parsons. Despite a sharp 20.4% decline in the 90 day share price return and a 10% year to date share price loss, Parsons still shows a 30.6% 5 year total shareholder return. This suggests that recent momentum has faded after a stronger multi year outcome. If you...

In early April 2026, McDonald’s announced a nationwide expansion of its cold beverage lineup in the US, adding energy drinks like the Red Bull Dragonberry Energizer and crafted sodas such as Dirty Dr Pepper, alongside value-focused menu adjustments and operational changes to improve cost control. This move signals McDonald’s bid to capture a larger share of the fast-growing beverage category by targeting younger and price-conscious consumers with lower-priced specialty drinks that broaden...

The United States market has experienced a notable upswing, climbing 4.4% in the last week and showing a robust 32% increase over the past year, with earnings forecasted to grow by 16% annually. In this thriving environment, identifying growth companies with high insider ownership can be particularly appealing as they often signal confidence from those closest to the business and potential alignment with shareholder interests.

The market has climbed 4.4% in the last 7 days and is up 32% over the past year, with earnings forecasted to grow by 16% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when they have solid financials. We've identified three penny stocks that combine balance sheet strength with potential for outsized gains, giving investors a chance to uncover hidden value in quality companies.

Over the last 7 days, the United States market has risen by 4.4%, contributing to a remarkable 32% increase over the past year, with earnings expected to grow by 16% annually. In this thriving environment, identifying stocks that combine solid fundamentals with growth potential can uncover promising opportunities for investors seeking undiscovered gems.

Over the last 7 days, the United States market has risen by 4.4%, contributing to a remarkable 32% increase over the past year, with earnings forecasted to grow by 16% annually. In this robust market environment, dividend stocks with yields of at least 3% can offer investors a combination of income and potential capital appreciation, making them an attractive option for those seeking steady returns amidst growth opportunities.

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

In recent days, KKR entered into a partnership with Samsung SDS, with KKR-managed funds committing KRW 1.22 trillion (about US$820 million) in newly issued convertible bonds to support Samsung SDS’s AI-focused infrastructure and global expansion plans. This move, alongside the earlier final close of KKR’s approximately US$23.00 billion North America Fund XIV, highlights how the firm is reinforcing both its capital base and its role as an active partner in technology-enabled growth. We’ll now...

If you are wondering whether United Parcel Service (UPS) is fairly priced or offering value right now, this breakdown will help you frame the stock through several valuation lenses. UPS recently closed at US$103.22, with returns of 5.8% over 7 days, 6.2% over 30 days, 2.2% year to date and 14.3% over 1 year, set against weaker 3 year and 5 year returns of 37.7% and 28.9% declines. These mixed return figures sit alongside ongoing attention on parcel volumes, pricing power and cost control,...

Earlier this month, BioCryst Pharmaceuticals, Inc. appointed Sandeep M. Menon, MD, PhD, a veteran of Alnylam and Pfizer, as Chief Research and Development Officer, bringing extensive experience in global clinical development, biostatistics and rare disease drug approvals. His background in advancing complex therapies like RNAi drugs and leading AI-enabled R&D organizations may meaningfully influence how BioCryst prioritizes and executes its future development pipeline. Next, we’ll explore...

If you are trying to figure out whether Fabrinet's share price reflects its real worth, this is the place to start. The stock last closed at US$681.68, with returns of 22.2% over 7 days, 35.8% over 30 days, 42.2% year to date, 261.6% over 1 year, 603.2% over 3 years, and a very large gain over 5 years. Recent coverage of Fabrinet has focused on its role in high performance optical and electronic manufacturing, as customers look for partners that can handle complex, high value hardware. This...

Earlier in fiscal 2026, Scotts Miracle-Gro reaffirmed its full-year guidance, saying the Iran War’s commodity disruptions should not affect its outlook, after securing over 80% of its commodity needs and sourcing roughly 90% of product costs domestically under existing contracts. The company also issued fiscal 2026 EPS guidance of US$4.15 to US$4.35, highlighting management’s confidence in gross margin recovery and growth plans despite external supply and cost uncertainties. Now we’ll...

Fresh capital and two-year high put Sigma Lithium in focus Sigma Lithium (SGML) is back on investor radars after securing a US$100 million collateralized bank guarantee for its Greentech Industrial Plant 2, alongside a recent move to a new two year share price high. See our latest analysis for Sigma Lithium. The recent move to a US$17.57 share price comes alongside a 58.72% 1 month share price return and 23.65% year to date share price return. The 1 year total shareholder return of 118.80%...

Earlier this month, Waystar announced an AI-powered recoupments solution, using its AltitudeAI platform and a dataset of over 7.50 billion healthcare payment transactions and US$2.40 trillion in annual gross claims, to uncover provider revenue quietly taken back through opaque post-payment adjustments. In early adopter deployments, the tool has cut reconciliation time by more than 80% and, for a health system with about US$4.00 billion in annual revenue, identified US$32.00 million in...

In early April 2026, Canva announced that PayPal Payment Links is now available directly within its platform, allowing 265 million monthly users to turn any digital or printed design into a PayPal-hosted checkout experience with links or QR codes, multiple currencies, and no website required. This integration highlights how PayPal is embedding payments into creative workflows, potentially deepening its reach among creators, entrepreneurs, and small businesses that monetize content across...